• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone.

作者信息

Bertuglia Giuseppe, Bringhen Sara, Bruno Benedetto, Impalà Giorgia Andrea, D'Agostino Mattia

机构信息

SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza di Torino, Torino, Italy.

Division of Hematology, Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza di Torino, University of Torino, Torino, Italy.

出版信息

Br J Haematol. 2025 Jan;206(1):16-17. doi: 10.1111/bjh.19887. Epub 2024 Nov 14.

DOI:10.1111/bjh.19887
PMID:39543460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11739761/
Abstract
摘要

相似文献

1
M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone.在接受达雷妥尤单抗、来那度胺和地塞米松治疗的多发性骨髓瘤患者中出现的与M蛋白相关的坏死性肉芽肿。
Br J Haematol. 2025 Jan;206(1):16-17. doi: 10.1111/bjh.19887. Epub 2024 Nov 14.
2
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗新诊断多发性骨髓瘤患者的MAIA研究的通俗易懂总结
Future Oncol. 2023 Apr;19(13):887-895. doi: 10.2217/fon-2023-0082. Epub 2023 May 22.
3
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
4
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗新诊断的依赖透析的多发性骨髓瘤患者后的肾脏恢复情况
CEN Case Rep. 2022 May;11(2):265-268. doi: 10.1007/s13730-021-00668-w. Epub 2021 Nov 24.
5
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.每周卡非佐米、来那度胺、地塞米松和达雷妥尤单抗联合治疗新诊断多发性骨髓瘤患者的安全性和有效性：MANHATTAN 非随机临床试验。
JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.
6
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤患者（GRIFFIN）：一项开放标签、随机、2 期试验的最终分析。
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
7
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
8
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
9
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.来那度胺联合地塞米松添加达雷妥尤单抗或硼替佐米治疗新诊断多发性骨髓瘤的成本效果分析。
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
10
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.PERSEUS 研究中达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松治疗初诊多发性骨髓瘤的通俗语言摘要。
Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.

本文引用的文献

1
Cutaneous manifestations of monoclonal gammopathy.单克隆丙种球蛋白病的皮肤表现。
Blood Cancer J. 2022 Apr 11;12(4):58. doi: 10.1038/s41408-022-00661-1.
2
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.一线免疫化疗治疗滤泡性淋巴瘤的疗效：一项随机对照试验的网络荟萃分析。
Blood Cancer J. 2022 Jan 5;12(1):1. doi: 10.1038/s41408-021-00598-x.
3
Necrobiotic xanthogranuloma treated with lenalidomide.来那度胺治疗坏死性黄色肉芽肿。
Clin Exp Dermatol. 2018 Apr;43(3):345-347. doi: 10.1111/ced.13293. Epub 2017 Oct 19.
4
Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review.成人眼眶及眼附属器黄色肉芽肿病：新的免疫组化发现及临床回顾
Br J Ophthalmol. 2006 May;90(5):602-8. doi: 10.1136/bjo.2005.085894.
5
Necrobiotic xanthogranuloma associated with myeloma.与骨髓瘤相关的坏死性黄色瘤。
J Eur Acad Dermatol Venereol. 2004 May;18(3):328-31. doi: 10.1111/j.1468-3083.2004.00906.x.